Clinical trial

A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

NCT05078931

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2021-10-27

PhasePHASE2

Study timeline

Study start (actual)2021-10-27Date precision: day

Registry last updated2025-07-30

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

NSCLCunresolved

Interventions

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

LenvatinibDRUG · verified · RxNorm: lenvatinib

Sponsors & collaborators

Shanghai Chest Hospitallead sponsor

Merck Sharp & Dohme LLCcollaborator

Mapped research locations

ShanghaiChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05078931 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.